

Fabio Mangiacapra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4073731/publications.pdf>

Version: 2024-02-01

114
papers

4,004
citations

159585
30
h-index

123424
61
g-index

121
all docs

121
docs citations

121
times ranked

4852
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet reactivity and clinical outcomes following percutaneous coronary intervention in complex higher-risk patients. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 135-140.	1.5	2
2	Impact of Mediterranean diet on metabolic and inflammatory status of patients with polyvascular atherosclerotic disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 117-124.	2.6	6
3	Prevalence and clinical impact of high platelet reactivity in patients with chronic kidney disease treated with percutaneous coronary intervention: An updated systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1086-1094.	1.7	1
4	In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. <i>Life</i> , 2022, 12, 393.	2.4	27
5	Prediction of type 4a myocardial infarction with the angiography-derived hemodynamic (ADDED) index. <i>Heart and Vessels</i> , 2022, 37, 1471-1477.	1.2	1
6	Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status. <i>American Journal of Cardiology</i> , 2022, 171, 49-54.	1.6	1
7	Invasive Assessment of Coronary Microvascular Function. <i>Journal of Clinical Medicine</i> , 2022, 11, 228.	2.4	17
8	Circadian variations of platelet reactivity on clopidogrel in patients treated with elective percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	2.1	0
9	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7261.	4.1	4
10	High value of mid-regional proadrenomedullin in COVID-19: A marker of widespread endothelial damage, disease severity, and mortality. <i>Journal of Medical Virology</i> , 2021, 93, 2820-2827.	5.0	29
11	Non-Invasive Functional and Anatomic vascular evaluation for the prediction of coronary artery disease: The NINFA study. <i>International Journal of Cardiology</i> , 2021, 322, 16-22.	1.7	3
12	Current management and prognosis of patients with recurrent myocardial infarction. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 731.	1.4	3
13	Prediction of 5-Year Mortality in Patients with Chronic Coronary Syndrome Treated with Elective Percutaneous Coronary Intervention: Role of the ACEF Score. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 1125-1130.	2.4	2
14	Impact of Chronic Kidney Disease and Platelet Reactivity on Clinical Outcomes Following Percutaneous Coronary Intervention. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 1085-1092.	2.4	2
15	Relationship between peripheral arterial reactive hyperemia and the index of myocardial resistance in patients undergoing invasive coronary angiography. <i>International Journal of Cardiology</i> , 2021, 333, 8-13.	1.7	5
16	Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. <i>Pharmacological Research</i> , 2021, 168, 105581.	7.1	26
17	Usefulness of Adding Pre-procedural Glycemia to the Mehran Score to Enhance Its Ability to Predict Contrast-induced Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention Development and Validation of a Predictive Model. <i>American Journal of Cardiology</i> , 2021, 155, 16-22.	1.6	10
18	To treat or not to treat intermediate coronary lesions: Are we asking the question wrong?. <i>International Journal of Cardiology</i> , 2021, 338, 37-38.	1.7	0

#	ARTICLE	IF	CITATIONS
19	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Coroner PatiEnts: the REDUCE registry. Coronary Artery Disease, 2021, 32, 281-287.	0.7	2
20	Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study. Journal of Diabetes Research, 2021, 2021, 1-9.	2.3	3
21	730 Prediction of type 4a myocardial infarction with the angiography-derived haemodynamic (added) index. European Heart Journal Supplements, 2021, 23, .	0.1	0
22	The Pivotal Role of Invasive Functional Assessment in Patients With Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA). Frontiers in Cardiovascular Medicine, 2021, 8, 781485.	2.4	7
23	Impact of Tourniquet Use on Systemic Inflammatory Parameters, Functional Physical Recovery, and Cardiovascular Outcomes of Patients Undergoing Knee Arthroplasty: A Case-Control Study. Journal of Knee Surgery, 2020, 33, 762-767.	1.6	3
24	Coronary microcirculation and peri-procedural myocardial injury during elective percutaneous coronary intervention. International Journal of Cardiology, 2020, 306, 42-46.	1.7	17
25	Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention. Journal of Cardiovascular Translational Research, 2020, 13, 668-675.	2.4	3
26	Microvascular impairment associated with percutaneous coronary revascularization: The quest for protective microcirculatory strategies. International Journal of Cardiology, 2020, 308, 9.	1.7	1
27	Endothelial dysfunction in patients with spontaneous coronary artery dissection: another brick in the failing coronary wall?. International Journal of Cardiology, 2020, 316, 52-53.	1.7	0
28	Role of endothelial dysfunction in determining angina after percutaneous coronary intervention: Learning from pathophysiology to optimize treatment. Progress in Cardiovascular Diseases, 2020, 63, 233-242.	3.1	13
29	Prevalence Of familial hypercholeSTERolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study. Atherosclerosis, 2020, 308, 32-38.	0.8	8
30	Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAL arTERy revascularization due to critical limb ischemia trial (INCORPORATE trial). American Heart Journal, 2019, 214, 107-112.	2.7	1
31	Relation of Platelet Indexes to Platelet Reactivity and Periprocedural Myocardial Infarction in Patients Who Underwent Percutaneous Coronary Angioplasty. American Journal of Cardiology, 2018, 121, 1027-1031.	1.6	6
32	Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis. Journal of Thrombosis and Thrombolysis, 2018, 45, 496-503.	2.1	11
33	Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention. Journal of Cardiovascular Translational Research, 2018, 11, 517-523.	2.4	34
34	Platelet reactivity and coronary microvascular impairment after percutaneous revascularization in stable patients receiving clopidogrel or prasugrel. Atherosclerosis, 2018, 278, 23-28.	0.8	18
35	Endothelial dysfunction as predictor of angina recurrence after successful percutaneous coronary intervention using second generation drug eluting stents. European Journal of Preventive Cardiology, 2018, 25, 1360-1370.	1.8	9
36	Fractional flow reserve (FFR) as a guide to treat coronary artery disease. Expert Review of Cardiovascular Therapy, 2018, 16, 465-477.	1.5	16

#	ARTICLE	IF	CITATIONS
37	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet</i> , The, 2018, 392, 835-848.	13.7	215
38	P2Y12 inhibition in STEMI: early, strong or both?. <i>EuroIntervention</i> , 2018, 14, 25-27.	3.2	1
39	Choosing the optimal antiplatelet therapy in atherosclerotic disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 566-567.	1.7	0
40	Platelet reactivity in patients carrying the e-NOS G894T polymorphism after a loading dose of aspirin plus clopidogrel. <i>Thrombosis Research</i> , 2017, 151, 72-73.	1.7	0
41	Correlation between serum uric acid levels and residual platelet reactivity in patients undergoing PCI. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 470-471.	2.6	1
42	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	2.8	132
43	Heart Rate reduction by Ivabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. <i>Clinical Research in Cardiology</i> , 2017, 106, 69-75.	3.3	25
44	Thrombus aspiration in primary percutaneous coronary intervention: still a valid option with improved technique in selected patients!. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S110-S114.	1.7	5
45	EXCEL and NOBLE: stents or surgery for left main stem stenosis?. <i>EuroIntervention</i> , 2017, 13, e604-e608.	3.2	2
46	Effects of Prasugrel Versus Clopidogrel on Coronary Microvascular Function in Patients Undergoing Elective PCI. <i>Journal of the American College of Cardiology</i> , 2016, 68, 235-237.	2.8	17
47	Idiopathic sensorineural hearing loss is associated with endothelial dysfunction. <i>IJC Heart and Vasculature</i> , 2016, 12, 32-33.	1.1	6
48	Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2016, 118, 980-984.	1.6	11
49	Clopidogrel Versus Ticagrelor for Antiplatelet Maintenance in Diabetic Patients Treated With Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 134, 835-837.	1.6	32
50	Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis. <i>International Journal of Cardiology</i> , 2016, 220, 629-633.	1.7	26
51	Efficacy and Safety of Paclitaxel-Coated Balloon for the Treatment of In-Stent Restenosis in High-Risk Patients. <i>American Journal of Cardiology</i> , 2015, 116, 1690-1694.	1.6	19
52	Incremental Value of Platelet Reactivity Over a Risk Score of Clinical and Procedural Variables in Predicting Bleeding After Percutaneous Coronary Intervention via the Femoral Approach. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	8
53	Glycemic Variability Assessed by Continuous Glucose Monitoring and Short-Term Outcome in Diabetic Patients Undergoing Percutaneous Coronary Intervention: An Observational Pilot Study. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-11.	2.3	16
54	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015, 36, 1762-1771.	2.2	297

#	ARTICLE	IF	CITATIONS
55	Comparison Among Patients â‰¥75 Years Having Percutaneous Coronary Angioplasty Using Drug-Eluting Stents Versus Bare Metal Stents. American Journal of Cardiology, 2015, 115, 1179-1184.	1.6	7
56	High platelet reactivity and periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: A significant association beyond definitions. International Journal of Cardiology, 2015, 190, 124-125.	1.7	14
57	Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC). Current Drug Targets, 2015, 16, 895-903.	2.1	25
58	ACEF and clinical SYNTAX score in the risk stratification of patients with heavily calcified coronary stenosis undergoing rotational atherectomy with stent implantation. Catheterization and Cardiovascular Interventions, 2014, 83, 1067-1073.	1.7	30
59	Relationship between time of day and periprocedural myocardial infarction after elective angioplasty. Chronobiology International, 2014, 31, 206-213.	2.0	13
60	Î± _{2A} -Adrenergic Receptor Polymorphism Potentiates Platelet Reactivity in Patients With Stable Coronary Artery Disease Carrying the Cytochrome P450 2C19*2 Genetic Variant. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1314-1319.	2.4	5
61	Thresholds for platelet reactivity to predict clinical events after coronary intervention are different in patients with and without diabetes mellitus. Platelets, 2014, 25, 348-356.	2.3	17
62	Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A "state-of-the-art" paper. European Heart Journal, 2014, 35, 2213-2223.	2.2	78
63	Evolving concepts of angiogram: fractional flow reserve discordances in 4000 coronary stenoses. European Heart Journal, 2014, 35, 2831-2838.	2.2	259
64	Impact of Chronic Kidney Disease on Platelet Reactivity and Outcomes of Patients Receiving Clopidogrel and Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1124-1129.	1.6	33
65	Clinical Implications of Platelet-Vessel Interaction. Journal of Cardiovascular Translational Research, 2013, 6, 310-315.	2.4	16
66	von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina. Journal of Cardiovascular Translational Research, 2013, 6, 364-370.	2.4	20
67	Long-term clinical outcome after fractional flow reserve versus angio-guided percutaneous coronary intervention in patients with intermediate stenosis of coronary artery bypass grafts. American Heart Journal, 2013, 166, 110-118.	2.7	52
68	Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease. Archives of Cardiovascular Diseases, 2013, 106, 554-561.	1.6	14
69	Quantitative angiography and optical coherence tomography for the functional assessment of nonobstructive coronary stenoses: Comparison with fractional flow reserve. American Heart Journal, 2013, 166, 1010-1018.e1.	2.7	39
70	Intracoronary Enalaprilat to Reduce Microvascular Damage During Percutaneous Coronary Intervention (ProMicro) Study. Journal of the American College of Cardiology, 2013, 61, 615-621.	2.8	53
71	Contrast-Induced Nephropathy in Patients Undergoing Primary Percutaneous Coronary Intervention Without Acute Left Ventricular Ejection Fraction Impairment. American Journal of Cardiology, 2013, 111, 684-688.	1.6	34
72	Stent thrombosis and platelet reactivity. Cor Et Vasa, 2013, 55, e151-e157.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Efficacy of Clopidogrel Reloading in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention During Chronic Clopidogrel Therapy (from the Antiplatelet Tj ETQq1 1 0.784314 rgBT /Overlock 10 ⁴ Tf 50 25	1.6	19
	American Journal of Cardiology, 2013, 112, 162-168.		
74	Correlation of Platelet Reactivity and C-Reactive Protein Levels to Occurrence of Peri-Procedural Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the Tj ETQq0 0 0 rgBT /Overlock 10 ⁴ Tf 50 697	1.6	19
75	Association of Biomarkers of Lipid Modification with Functional and Morphological Indices of Coronary Stenosis Severity in Stable Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2013, 6, 536-544.	2.4	10
76	Letter by Mangiacapra and Barbato Regarding Article, "Effects of Endothelial Dysfunction on Residual Platelet Aggregability After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery Disease" • Circulation: Cardiovascular Interventions, 2013, 6, e65.	3.9	0
77	Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, 604-611.	1.7	13
78	Influence of transradial versus transfemoral diagnostic heart catheterisation on peripheral vascular endothelial function. EuroIntervention, 2013, 8, 1252-1258.	3.2	16
79	Pressure-Diameter Relationship in Human Coronary Arteries. Circulation: Cardiovascular Interventions, 2012, 5, 791-796.	3.9	15
80	Long-Term Clinical Outcome After Fractional Flow Reserve-Guided Percutaneous Coronary Revascularization in Patients With Small-Vessel Disease. Circulation: Cardiovascular Interventions, 2012, 5, 62-68.	3.9	78
81	High cholesterol levels are associated with coronary microvascular dysfunction. Journal of Cardiovascular Medicine, 2012, 13, 439-442.	1.5	16
82	Circadian variations of ischemic burden among patients with myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal, 2012, 163, 208-213.	2.7	60
83	Comparison of drug-eluting versus bare-metal stents after rotational atherectomy for the treatment of calcified coronary lesions. International Journal of Cardiology, 2012, 154, 373-376.	1.7	28
84	NT-proANP circulating level is a prognostic marker in stable ischemic heart disease. International Journal of Cardiology, 2012, 155, 311-312.	1.7	16
85	Antiplatelet effect of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an analysis of the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during) Tj ETQq1 1 0.784314 rgBT /Overlock 10 ⁴ Tf 50 25	1.7	19
86	Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2012, 10, 2452-2461.	3.8	34
87	Influence of rs5065 Atrial Natriuretic Peptide Gene Variant on Coronary Artery Disease. Journal of the American College of Cardiology, 2012, 59, 1763-1770.	2.8	40
88	Platelet Reactivity and Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 60, 378-380.	2.8	0
89	TCT-56 Incremental value of platelet reactivity over a risk score of clinical and procedural variables in predicting bleeding events after percutaneous coronary intervention. Journal of the American College of Cardiology, 2012, 60, B17.	2.8	0
90	A Therapeutic Window for Platelet Reactivity for Patients Undergoing Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 281-289.	2.9	82

#	ARTICLE	IF	CITATIONS
91	Prognostic role of preprocedural glucose levels on short- and long-term outcome in patients undergoing percutaneous coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 377-384.	1.7	19
92	Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1592-1599.	2.8	107
93	Long-Term Follow-Up After Fractional Flow Reserve-Guided Treatment Strategy in Patients With an Isolated Proximal Left Anterior Descending Coronary Artery Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1175-1182.	2.9	95
94	Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. <i>American Heart Journal</i> , 2011, 162, 907-913.	2.7	24
95	Optimizing Revascularization Strategies in Coronary Artery Disease for Optimal Benefit to Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 630-633.	4.7	3
96	From SYNTAX to FAME, a paradigm shift in revascularization strategies. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 538-542.	1.5	18
97	Clopidogrel discontinuation and platelet reactivity following coronary stenting. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 24-32.	3.8	32
98	Functional SYNTAX Score for Risk Assessment in Multivessel Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1211-1218.	2.8	251
99	Lack of correlation between platelet reactivity and glycaemic control in type 2 diabetes mellitus patients treated with aspirin and clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 54-58.	2.1	12
100	Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600- μ g clopidogrel. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 64-71.	2.1	33
101	Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 458-466.	3.2	14
102	Translesional Pressure Gradients to Predict Blood Pressure Response After Renal Artery Stenting in Patients With Renovascular Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 537-542.	3.9	108
103	Effective Radiation Dose, Time, and Contrast Medium to Measure Fractional Flow Reserve. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 821-827.	2.9	41
104	Relation of Endothelial Function to Residual Platelet Reactivity After Clopidogrel in Patients With Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 333-338.	1.6	35
105	Comparison of Platelet Reactivity and Periprocedural Outcomes in Patients With Versus Without Diabetes Mellitus and Treated With Clopidogrel and Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 106, 619-623.	1.6	72
106	Comparison of 600 Versus 300-mg Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Angioplasty. <i>American Journal of Cardiology</i> , 2010, 106, 1208-1211.	1.6	55
107	Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: A real-world registry. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 70-76.	1.7	30
108	High Residual Platelet Reactivity After Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 35-40.	2.9	65

#	ARTICLE	IF	CITATIONS
109	Point-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 318-323.	2.9	54
110	Fractional Flow Reserve for the Assessment of Nonculprit Coronary Artery Stenoses in Patients With Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2010, 3, 1274-1281.	2.9	281
111	Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of) Tj ETQq1 1 0.7843142gBT /Overclock 10	1.4	4
112	Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine, 2010, 4, 421-434.	2.2	3
113	Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 121-130.	2.8	340
114	Point-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2008, 52, 1128-1133.		